{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:22:12Z","timestamp":1792671732011,"version":"4.5.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n In men with metastatic hormone-sensitive prostate cancer (mHSPC), prostate-specific antigen (PSA) decline after treatment has been associated with improved survival. However, the data on PSA decline are limited in men with mHSPC after treatment with enzalutamide plus androgen deprivation therapy (ADT).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association of enzalutamide plus ADT in men with mHSPC by PSA level at study enrollment in individuals with prior ADT and by degree of PSA reduction with clinical end points.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This post hoc secondary analysis was performed on data collected from the ARCHES multinational, double-blind, phase 3 randomized clinical trial. In the ARCHES trial, men with mHSPC were randomized between March 21, 2016, and January 12, 2018. Analyses were performed in October 2018 (median follow-up, 14.4 months; IQR, 11.2-17.7 months) and May 2021 (median follow-up, 44.6 months; IQR, 41.3-48.6 months).<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Patients were randomized 1:1 to enzalutamide (160 mg\/d) plus ADT or placebo plus ADT. ADT received for 3 to 6 months before study enrollment was permitted.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Radiographic progression-free survival (rPFS) and overall survival (OS) were correlated post hoc with PSA level at enrollment in patients with prior ADT and additionally with PSA decline at 6 months or undetectable PSA (&amp;lt;0.2 ng\/mL) during study treatment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 1150 men (median age, 70 years; range, 46-92 years) were enrolled. Improvement in clinical outcomes such as rPFS was seen with enzalutamide plus ADT in men with PSA levels at enrollment of 0.2 to 4 ng\/mL and above 4 ng\/mL. Hazard ratios (HRs) for improved rPFS in men with PSA levels up to 0.2 ng\/mL, above 0.2 to 4 ng\/mL, and above 4 ng\/mL were 0.59 (95% CI, 0.27-1.30), 0.32 (95% CI, 0.20-0.50), and 0.44 (95% CI, 0.32-0.62), respectively. Patients treated with enzalutamide plus ADT who achieved undetectable PSA had an 86.0% reduced risk of radiographic disease progression (HR, 0.14 [95% CI, 0.09-0.23];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and a 76.0% reduced risk of death (HR, 0.24 [95% CI, 0.17-0.34];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this secondary analysis of a randomized clinical trial, patients with mHSPC treated with enzalutamide plus ADT vs placebo plus ADT had improved clinical outcomes regardless of PSA level at enrollment. Undetectable PSA was associated with improved clinical outcomes with enzalutamide treatment. Future studies are required to further characterize the clinical utility of further treatment intensification among men with mHSPC for whom ADT plus enzalutamide fails to achieve undetectable PSA.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02677896<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.8751","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T11:52:01Z","timestamp":1746618721000},"page":"e258751","source":"Crossref","is-referenced-by-count":20,"title":["Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Arun A.","family":"Azad","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Petrylak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Kanazawa Medical University, Ishikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[{"name":"Department of Urology, Carolina Urologic Research Center, Myrtle Beach, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnauld","family":"Villers","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Centre, Lille University, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gomez-Veiga","sequence":"additional","affiliation":[{"name":"Department of Urology, Complexo Hospitalario Universitario de A Coru\u00f1a, Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Alcaraz","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Alekseev","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hertzen Moscow Cancer Research Institute, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell Z.","family":"Szmulewitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Holzbeierlein","sequence":"additional","affiliation":[{"name":"Department of Urologic Oncology, The University of Kansas Medical Center, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Rosbrook","sequence":"additional","affiliation":[{"name":"Department of Global Biometrics and Data Management, Pfizer Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[{"name":"Biostatistics, Astellas Pharma Inc, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Zohren","sequence":"additional","affiliation":[{"name":"Oncology, Pfizer Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader N.","family":"El-Chaar","sequence":"additional","affiliation":[{"name":"Medical Affairs, Astellas Pharma Inc, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel P.","family":"Haas","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Astellas Pharma Inc, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital, Eberhard Karls University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Divisions of Medical Oncology and Urology, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"32","key":"zoi250319r3","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi250319r4","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer.","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi250319r5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12894-018-0353-4","article-title":"Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer.","volume":"18","author":"Sato","year":"2018","journal-title":"BMC Urol"},{"issue":"3","key":"zoi250319r6","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/JU.0000000000003084","article-title":"Nadir prostate-specific antigen as an independent predictor of survival outcomes: a post hoc analysis of the PROSPER randomized clinical trial.","volume":"209","author":"Hussain","year":"2023","journal-title":"J Urol"},{"issue":"6","key":"zoi250319r7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.euo.2018.11.005","article-title":"Prognostic association of prostate-specific antigen decline with clinical outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide in a randomized clinical trial.","volume":"2","author":"Armstrong","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"25","key":"zoi250319r8","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi250319r9","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnci\/djj129","article-title":"Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.","volume":"98","author":"Petrylak","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"zoi250319r10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel.","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"zoi250319r11","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi250319r12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"zoi250319r13","doi-asserted-by":"publisher","first-page":"viii273","DOI":"10.1093\/annonc\/mdy284.006","article-title":"LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO).","volume":"29","author":"Matsubara","year":"2018","journal-title":"Ann Oncol"},{"issue":"16","key":"zoi250319r14","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1200\/JCO.2022.40.16_suppl.5078","article-title":"Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.","volume":"40","author":"Saad","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi250319r15","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003257.01","article-title":"MP29-01. Rapid, durable, and deep prostate-specific antigen response following addition of darolutamide to androgen-deprivation therapy and docetaxel in ARASENS.","volume":"209","author":"Saad","year":"2023","journal-title":"J Urol"},{"issue":"20","key":"zoi250319r16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"zoi250319r17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","article-title":"Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study.","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"issue":"16","key":"zoi250319r18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer.","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250319r19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","article-title":"Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL trial.","volume":"78","author":"Armstrong","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"zoi250319r20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/JU.0000000000003361.09","article-title":"LBA02-09. EMBARK: a phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer.","volume":"210","author":"Shore","year":"2023","journal-title":"J Urol"},{"issue":"8","key":"zoi250319r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101644","article-title":"HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.","volume":"5","author":"Sharifi","year":"2024","journal-title":"Cell Rep Med"},{"key":"zoi250319r1","unstructured":"Xtandi highlights of prescribing information. US Food and Drug Administration. Accessed December 14, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213674s010,203415s022lbl.pdf"},{"key":"zoi250319r2","unstructured":"Xtandi summary of product characteristics. European Medicines Agency. Accessed December 14, 2023. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2018\/20180208139836\/anx_139836_en.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2833622\/azad_2025_oi_250319_1745961533.91608.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T11:52:04Z","timestamp":1746618724000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2833622"}},"subtitle":["A Secondary Analysis of the ARCHES Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.8751","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}